Berna Beverloo

Mutations in a TGF-β Ligand, TGFB3, Cause Syndromic Aortic Aneurysms and Dissections

Aida M. Bertoli‐Avella, Elisabeth Gillis, Hiroko Morisaki et al. · Journal of the American College of Cardiology · 2015 · 290 citations · Full text

Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium

C. Michel Zwaan, Carmelo Rizzari, Françoise Méchinaud et al. · Journal of Clinical Oncology · 2013 · 93 citations · Full text

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt et al. · Blood · 2010 · 88 citations

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high‐dose chemotherapy in patients with multiple myeloma

Ka Lung Wu, Berna Beverloo, Henk M. Lokhorst et al. · British Journal of Haematology · 2007 · 73 citations

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

Pieter Sonneveld, Bronno van der Holt, I G Schmidt-Wolf et al. · Blood · 2008 · 66 citations